Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label bintrafusp alfa monotherapy in cervical cancer
2019-003583-40Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in Cervical Cancer (CC), sponsored by Merck KGaA. Primary endpoint: Confirmed objective response. Started Apr 2020; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2019-003583-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003583-40.